Bluegrass Pharmaceuticals
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Websites | |
| NAICS | 541714 |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at Bluegrass Pharmaceuticals
Ben Register
Co-Founder
About Bluegrass Pharmaceuticals
Research increasingly demonstrates that an over-active immune system and the resulting spikes in inflammation, are actually worse for healing. When injury first occurs, tissue specific macrophages initiate the inflammatory cascade by releasing cytokines into the blood stream. These inflammatory markers recruit additional macrophages to the site of injury. In chronic or deleterious forms of inflammation, these recruited macrophages arrive at the scene in M1 or “destructive” phenotype, long after necrotic tissue or pathogens are removed; causing unnecessary damage and perpetuating the cycle of inflammation. Our NF-kB blocker leverages a nano-particle delivery system to target and re-polarize recruited macrophages to the M2 or “restorative” phenotype, moderating inflammation and improving remodeling.
Bluegrass Pharmaceuticals revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Bluegrass Pharmaceuticals has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Bluegrass Pharmaceuticals has never raised funding before.
United Arab Emirates
United Kingdom
Canada
Italy
Frequently asked questions
4.8
40,000 users
